Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility i...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 707214
Main Authors Tung, Iris, Sahu, Arvind
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 30.08.2021
Subjects
anti-VEGF (vascular endothelial growth factor) agents
biomarker
immune checkpoint inhibition (ICI)
metastatic renal carcinoma
Oncology
tyrosine kinase inhibitions (TKIs) therapy
Online AccessGet full text

Cover

More Information
Summary:The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility is limited by short-lived efficacy and rapid disease progression. The dysregulation of immune cells in the tumour microenvironment contributes to unregulated growth of RCC. Thus, the use of immune checkpoint inhibitors has become first-line treatment for metastatic RCC and has offered dramatic improvement in clinical benefit and survival. Treatment with immune checkpoint inhibitor in combination with TKI appears to be promising in offering even greater response rates. The treatment for metastatic RCC continues to evolve and ongoing advances with new targeted agents and biomarkers are needed to continue to improve prognosis in the future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Vincenzo Di Nunno, AUSL Bologna, Italy; Amin Nassar, Brigham and Women’s Hospital and Harvard Medical School, United States; Mamta Parikh, UC Davis Health, United States
Edited by: Alessia Cimadamore, Marche Polytechnic University, Italy
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.707214